Features of the course of non-ST elevation myocardial infarction in patients with a history of COVID-19

Aim      To study the clinical course of non-ST segment elevation myocardial infarction (NSTEMI) in hospitalized patients after COVID-19 and to evaluate the effect of baseline characteristics of patients on the risk of complications.

Material and methods  The study included 209 patients with NSTEMI; 104 of them had had COVID-19. The course of myocardial infarction (MI) was analyzed at the hospital stage, including evaluation of the incidence rate of complications (fatal outcome, recurrent MI, life-threatening arrhythmias and conduction disorders, pulmonary edema, cardiogenic shock, ischemic stroke, gastrointestinal bleeding).

Results Mean age of patients after COVID-19 was 61.8±12.2 years vs. 69.0±13.0 in the comparison group (p<0.0001). The groups were comparable by risk factors, clinical data, and severity of coronary damage. Among those who have had СOVID-19, there were fewer patients of the GRACE high risk group (55.8 % vs. 74.3 %; p<0.05). Convalescent COVID-19 patients had higher levels of C-reactive protein and troponin I (p<0.05). The groups did not significantly differ in the incidence of unfavorable NSTEMI course (p>0.05). However, effects of individual factors (postinfarction cardiosclerosis, atrial fibrillation, decreased SpO2, red blood cell concentration, increased plasma glucose) on the risk of complications were significantly greater for patients after COVID-19 than for the control group (p<0.05).

Conclusion      Patients with NSTEMI, despite differences in clinical history and laboratory data, are characterized by a similar risk of death at the hospital stage, regardless of the past COVID-19. Despite the absence of statistically significant differences in the incidence of in-hospital complications, in general, post-COVID-19 patients showed a higher risk of complicated course of NSTEMI compared to patients who had not have COVID-19. In addition, for this category of patients, new factors were identified that previously did not exert a clinically significant effect on the incidence of complications: female gender, concentration of IgG to SARS-CoV-2 ≥200.0 U/l, concentration of С-reactive protein ≥40.0 mg/l, total protein <65 g/l. These results can be used for additional stratification of risk for cardiovascular complications in patients with MI and also for development of individual protocols for evaluation and management of NSTEMI patients with a history of COVID-19.

1. Prati F, Marco V, Paoletti G, Albertucci M. Coronary inflammation: why searching, how to identify and treat it. European Heart Journal Supplements. 2020;22(Suppl E):E121–4. DOI: 10.1093/eurheartj/suaa076

2. Chughtai AA, Tan TC, Hitchen EM, Kunasekaran M, MacIntyre CR. Association of influenza infection and vaccination with cardiac biomarkers and left ventricular ejection fraction in patients with acute myocardial infarction. IJC Heart & Vasculature. 2020;31:100648. DOI: 10.1016/j.ijcha.2020.100648

3. Vejpongsa P, Kitkungvan D, Madjid M, Charitakis K, Anderson HV, Arain S et al. Outcomes of Acute Myocardial Infarction in Patients with Influenza and Other Viral Respiratory Infections. The American Journal of Medicine. 2019;132(10):1173–81. DOI: 10.1016/j.amjmed.2019.05.002

4. Muscente F, De Caterina R. Causal relationship between influenza infection and risk of acute myocardial infarction: pathophysiological hypothesis and clinical implications. European Heart Journal Supplements. 2020;22(Suppl E):E68–72. DOI: 10.1093/eurheartj/suaa064

5. Fracassi F, Niccoli G, Cosentino N, Eligini S, Fiorelli S, Fabbiocchi F et al. Human monocyte-derived macrophages: Pathogenetic role in plaque rupture associated to systemic inflammation. International Journal of Cardiology. 2021;325:1–8. DOI: 10.1016/j.ijcard.2020.09.071

6. Fadeev G.A., Fatykhov R.G., Tsibulkin N.A., Mikhoparova O.Yu., Oshchepkova O.B., Abdrakhmanova A.I. Inflammatory mechanisms in genesis of atherosclerosis. The Bulletin of Contemporary Clinical Medicine. 2020;13(6):62–7. DOI: 10.20969/VSKM.2020.13(6).62-67

7. Kaminski KA, Kozuch M, Bonda T, Wojtkowska I, Kozieradzka A, Dobrzycki S et al. Coronary sinus concentrations of interleukin-6 and its soluble receptors are affected by reperfusion and may portend complications in patients with myocardial infarction. Atherosclerosis. 2009;206(2):581–7. DOI: 10.1016/j.atherosclerosis.2009.03.033

8. Soldatova O.V., Kubyshkin A.V., Ushakov A.V., Gordienko A.I., Fomochkina I.I., Gagarina A.A. Proinflammatory cytokines changes in clinical course of acute myocardial infarction. Bulletin of Siberian Medicine. 2017;16(1):92–100. DOI: 10.20538/1682-0363-2017-1-92-100

9. Scalese M, Trivellini G, Sposato B. Public health and clinical approach to proactive Prevalence of symptoms-based diagnosis of mild SARSCoV- 2 infection in southern Tuscany. Annali di igiene. 2021;33(6):533–42. DOI: 10.7416/ai.2021.2435

10. Chashchin M.G., Gorshkov A.Yu., Drapkina O.M. Acute coronary syndrome in COVID-19 patients. Cardiovascular Therapy and Prevention. 2021;20(5):107–14. DOI: 10.15829/1728-8800-2021-2806

11. Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clinical Chemistry and Laboratory Medicine (CCLM). 2020;58(7):1021–8. DOI: 10.1515/cclm-2020-0369

12. Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Medicine. 2020;46(6):1089–98. DOI: 10.1007/s00134-020-06062-x

13. Lam MH-B, Wing YK, Yu MWM, Leung CM, Ma RCW, Kong APS et al. Mental Morbidities and Chronic Fatigue in Severe Acute Respiratory Syndrome Survivors: Long-term Follow-up. Archives of Internal Medicine. 2009;169(22):2142–7. DOI: 10.1001/archinternmed.2009.384

14. Chen C, Chen C, Yan JT, Zhou N, Zhao JP, Wang DW. Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48(7):567–71. DOI: 10.3760/cma.j.cn112148-20200225-00123

15. Liu PP, Blet A, Smyth D, Li H. The Science Underlying COVID-19: Implications for the Cardiovascular System. Circulation. 2020;142:68–78. DOI: 10.1161/CIRCULATIONAHA.120.047549

16. Wu J, Mamas M, Rashid M, Weston C, Hains J, Luescher T et al. Patient response, treatments, and mortality for acute myocardial infarction during the COVID-19 pandemic. European Heart Journal - Quality of Care and Clinical Outcomes. 2021;7(3):238–46. DOI: 10.1093/ehjqcco/qcaa062

17. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA et al. Fourth universal definition of myocardial infarction (2018). European Heart Journal. 2019;40(3):237–69. DOI: 10.1093/eurheartj/ehy462

18. Chashchin M.G., Gorshkov A.Yu., Drapkina O.M., Kositsyna I.V., Golubev A.V., Chaus N.I. et al. Clinical and anamnestic characteristics of patients with non-ST elevation myocardial infarction after COVID-19. Cardiovascular Therapy and Prevention. 2021;20(7):15–23. DOI: 10.15829/1728-8800-2021-3062

19. Erlikh A.D. Twelve months outcomes in patients with acute coronary syndrome, by the national registry RECORD-3. Russian Journal of Cardiology. 2018;23(3):23–30. DOI: 10.15829/1560-4071-2018-3-23-30

20. Tang EW, Wong C-K, Herbison P. Global Registry of Acute Coronary Events (GRACE) hospital discharge risk score accurately predicts long-term mortality post acute coronary syndrome. American Heart Journal. 2007;153(1):29–35. DOI: 10.1016/j.ahj.2006.10.004

21. Erlikh A.D. The First Moscow Acute Coronary Syndrome Registry: the results of six-month follow-up. Emergency Cardiology. 2014;2:3–9.

22. Diaz-Arocutipa C, Saucedo-Chinchay J, Imazio M. Pericarditis in patients with COVID-19: a systematic review. Journal of Cardiovascular Medicine. 2021;22(9):693–700. DOI: 10.2459/JCM.0000000000001202

23. Ramadan MS, Bertolino L, Zampino R, Durante-Mangoni E, Iossa D, Bertolino L et al. Cardiac sequelae after coronavirus disease 2019 recovery: a systematic review. Clinical Microbiology and Infection. 2021;27(9):1250–61. DOI: 10.1016/j.cmi.2021.06.015

24. Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J et al. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19). JAMA Cardiology. 2020;5(11):1265–73. DOI: 10.1001/jamacardio.2020.3557

25. Fox K, Prokup JA, Butson K, Jordan K. Acute Effusive Pericarditis: A Late Complication of COVID-19. Cureus. 2020;12(7):e9074. DOI: 10.7759/cureus.9074

26. Manolis AS, Manolis TA. Long COVID: An Emerging Puzzle. Rhythmos. 2021;16(1):89–94. [Av. at: http://rhythmos.gr/index.php/Rhythmos/article/download/497/274]

27. Cascino TM, Desai AA, Kanthi Y. At a crossroads: coronavirus disease 2019 recovery and the risk of pulmonary vascular disease. Current Opinion in Pulmonary Medicine. 2021;27(5):342–9. DOI: 10.1097/MCP.0000000000000792

28. De Filippo O, Gatti P, Rettegno S, Iannaccone M, D’Ascenzo F, Lazaros G et al. Is pericardial effusion a negative prognostic marker? Metaanalysis of outcomes of pericardial effusion. Journal of Cardiovascular Medicine. 2019;20(1):39–45. DOI: 10.2459/JCM.0000000000000720

29. Haeck MLA, Hoogslag GE, Boden H, Velders MA, Katsanos S, al Amri I et al. Prognostic Implications of Elevated Pulmonary Artery Pressure After ST-Segment Elevation Myocardial Infarction. The American Journal of Cardiology. 2016;118(3):326–31. DOI: 10.1016/j.amjcard.2016.05.008

30. Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infectious Diseases. 2021;53(10):737–54. DOI: 10.1080/23744235.2021.1924397